An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

NCT03137160 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Pyoderma Gangrenosum

Interventions

BIOLOGICAL: Ixekizumab

Sponsor

Ohio State University

Collaborators

[object Object]